Telitacicept + Placebo
Phase 3RecruitingInterest: 41/100
41
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Primary Sjogren's Disease
Conditions
Primary Sjogren's Disease
Trial Timeline
Feb 26, 2026 → Aug 1, 2028
NCT ID
NCT07404865About Telitacicept + Placebo
Telitacicept + Placebo is a phase 3 stage product being developed by Vor Biopharma for Primary Sjogren's Disease. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07404865. Target conditions include Primary Sjogren's Disease.
What happened to similar drugs?
20 of 20 similar drugs in Primary Sjogren's Disease were approved
Approved (20) Terminated (6) Active (0)
Hype Score Breakdown
Clinical
17
Activity
15
Company
9
Novelty
0
Community
0
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07404865 | Phase 3 | Recruiting |
| NCT06456567 | Phase 3 | Withdrawn |
| NCT06456580 | Phase 3 | Recruiting |
| NCT05306574 | Phase 3 | Terminated |
Competing Products
20 competing products in Primary Sjogren's Disease